NK

NantKwest
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.00
-0.74
-9.56%
After Hours: 6.80 -0.2 -2.86% 17:51 09/23 EDT
OPEN
7.76
PREV CLOSE
7.74
HIGH
7.85
LOW
6.92
VOLUME
784.42K
TURNOVER
--
52 WEEK HIGH
15.70
52 WEEK LOW
1.040
MARKET CAP
755.79M
P/E (TTM)
-9.8954
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET.
Business Wire · 2d ago
NantKwest's NK-92 bioanalytical testing line licensed to Fresenius Kabi SwissBioSim
NantKwest's ([[NK]] +2.0%) affiliate and exclusively-licensed distributor of its proprietary off-the-shelf NK-92® natural killer cells, Brink Biologics, has licensed its natural killer-based bioanalytical testing solution, to Fresenius Kabi SwissBioSim.Brink Biologics offers NK-92 based
Seekingalpha · 09/10 14:49
NantKwest Affiliate Brink Biologics Reports License Deal With Fresenius Kabi; Fresenius Has Joined List Of Companies Using Brink's NK-92 Cell Line For Bioanalytical Testing
Brink Biologics, Inc. ("Brink"), a NantKwest, Inc. (NASDAQ:NK) affiliate and exclusively-licensed distributor of NantKwest's proprietary off-the-shelf NK-92® natural killer cells in certain fields,
Benzinga · 09/10 13:10
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
Brink Biologics, Inc. ("Brink"), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytical testing solution
Business Wire · 09/10 13:00
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating
Business Wire · 08/24 14:00
NantKwest joins COVID-19 vaccine hopefuls with ImmunityBio deal
NantKwest (NASDAQ:NK) inks an agreement with privately held ImmunityBio to develop, manufacture and commercialize vaccines and therapeutics for COVID-19. U
Seeking Alpha - Article · 08/24 13:20
NantKwest And ImmunityBio Sign Collaboration Agreement For Joint Development, Manufacturing, Marketing, And Commercialization Of COVID-19 Vaccine And Related Therapeutics
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the
Benzinga · 08/24 13:02
Do Insiders Own Lots Of Shares In NantKwest, Inc. (NASDAQ:NK)?
If you want to know who really controls NantKwest, Inc. (NASDAQ:NK), then you'll have to look at the makeup of its...
Simply Wall St. · 08/19 15:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NK. Analyze the recent business situations of NantKwest through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NK stock price target is 13.00 with a high estimate of 18.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 116
Institutional Holdings: 11.22M
% Owned: 10.39%
Shares Outstanding: 107.97M
TypeInstitutionsShares
Increased
24
3.69M
New
57
2.64M
Decreased
9
1.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Director
Patrick Soon-Shiong
President/Chief Administrative Officer/Director
Barry Simon
Chief Financial Officer
Sonja Nelson
Lead Director/Independent Director
Frederick Driscoll
Director
Cheryl Cohen
Independent Director
Michael Blaszyk
Independent Director
John Thomas
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NK
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nantkwest Inc stock information, including NASDAQ:NK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NK stock methods without spending real money on the virtual paper trading platform.